<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129299">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01725776</url>
  </required_header>
  <id_info>
    <org_study_id>ICM 06-888</org_study_id>
    <nct_id>NCT01725776</nct_id>
  </id_info>
  <brief_title>Inhaled Milrinone in Cardiac Surgery</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic of Inhaled Milrinone in Cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital St. Justine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the concentration-effect relationship of inhaled
      milrinone after prophylactic administration in cardiac surgical patients with preoperative
      pulmonary hypertension undergoing cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Milrinone elimination will be verify with blood and urine samples analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Study the elimination rate of milrinone administered by inhalation</measure>
    <time_frame>up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate the presence or absence of hemodynamic and echographic effects observed after inhalation of milrinone</measure>
    <time_frame>15 min after the of study drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hemodynamic values evaluated will be: central venous pressure, systolic and diastolic pulmonary pressure, wedge, cardiac output, cardiac frequency, systolic and diastolic pressure, SaO2, EtCO2. Patient will also have arterial and venous gaz.  Echographic values will be evaluated to see the cardiac fonction: left and right ventricular systolic and diastolic function and valvular function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmation of the safety of inhaled milrinone</measure>
    <time_frame>24 hours after cardiac surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Verification of the absence of deleterious effects on cardiac output and systemic arterial pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the efficacy of inhaled milrinone in the treatment of pulmonary hypertension</measure>
    <time_frame>15 min after end of milrinone administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy in the treatment of pulmonary hypertension is defined as a reduction of the mean pulmonary pressure of 10-20 %</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Inhaled milrinone 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled milrinone 5 mg(as for the injectable solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled milrinone 5 mg</intervention_name>
    <description>Inhaled milrinone 5 mg (as for the injectable solution)</description>
    <arm_group_label>Inhaled milrinone 5 mg</arm_group_label>
    <other_name>Primacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective cardiac surgery under CPB

          -  High risk patients: NYHA class II-III

          -  Preoperative diagnostic of pulmonary hypertension:

               -  Systolic pulmonary artery pressure (sPAP) &gt; 35 mm Hg; or

               -  Mean pulmonary artery pressure (mPAP) &gt; 25 mm Hg; or

               -  mAP/mPAP &lt; 3.0 (after induction of anesthesia).

        Exclusion Criteria:

          -  Open Heart Surgery

          -  Contraindication to transesophageal echocardiography (TEE)

          -  Hemodynamic instability before surgery

          -  Emergency surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrée Denault, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 8, 2012</lastchanged_date>
  <firstreceived_date>June 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Andre Denault</investigator_full_name>
    <investigator_title>MD PhD FRCPC ABIM-CCM</investigator_title>
  </responsible_party>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Cardiopulmonary Bypass (CPB)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
